This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
by Zacks Equity Research
IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024. Stock falls.
Astrazeneca (AZN) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
Astrazeneca (AZN) reachead $64.69 at the closing of the latest trading day, reflecting a +1.32% change compared to its last close.
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
by Zacks Equity Research
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
by Kinjel Shah
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Are Options Traders Betting on a Big Move in AstraZeneca (AZN) Stock?
by Zacks Equity Research
Investors need to pay close attention to AstraZeneca (AZN) stock based on the movements in the options market lately.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.
Merck Q3 Earnings & Sales Top, Stock Down on Lowered '24 View
by Zacks Equity Research
MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales performance of the Gardasil vaccines.
Amgen Q3 Earnings Beat, Sales In Line, Obesity Candidate in Focus
by Zacks Equity Research
AMGN beats third-quarter estimates for earnings and matches the same for sales. It slightly raises 2024 sales guidance but narrows the EPS range.
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines, Mounjaro and Zepbound.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
by Zacks Equity Research
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Novartis Beats on Q3 Earnings and Sales, Raises 2024 Outlook
by Zacks Equity Research
NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its outlook for 2024.
Astrazeneca (AZN) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $75.05, moving -1.12% from the previous trading session.
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
by Kinjel Shah
Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.
Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?
by Kinjel Shah
Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
Sanofi Q3 Earnings Beat, Dupixent, New Drugs, Vaccines Drive Sales
by Zacks Equity Research
SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.
Should You Buy, Sell or Hold Pfizer Stock Before Q3 Earnings?
by Zacks Equity Research
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
AstraZeneca Receives CHMP's Approval for Wainzua in Europe
by Zacks Equity Research
The CHMP recommends approval for AZN's Wainzua for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis.
The Zacks Analyst Blog Highlights AstraZeneca, Accenture, AT&T and National Presto Industries
by Zacks Equity Research
AstraZeneca, Accenture, AT&T and National Presto Industries are part of the Zacks top Analyst Blog.
Top Research Reports for AstraZeneca, Accenture & AT&T
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), Accenture plc (ACN) and AT&T Inc. (T), as well as a micro-cap stock National Presto Industries, Inc. (NPK).
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals
by Zacks Equity Research
The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
by Zacks Equity Research
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.